LABA/LAMA in the treatment of chronic obstructive pulmonary disease based on the latest research results

Małgorzata Farnik

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

1/2018
vol. 4

Send email

Copy url:

abstract:

Review paper

LABA/LAMA in the treatment of chronic obstructive pulmonary disease based on the latest research results

Małgorzata Farnik

Online publish date: 2018/03/12

View full text Get citation

Chronic obstructive pulmonary disease (COPD) is characterised by progressive irreversible airflow limitation and exercise intolerance. Bronchodilators are the first-choice treatment in COPD. According to the guidelines in stable CO PD treatment, long-acting bronchodilators – long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) – are recommended. It was found that LAMA and LABA improve lung function, and decrease dyspnoea and exacerbation risk. Recently published data compare different treatment options including bronchodilator monotherapy and bronchodilator combination (LABA/LAMA) as well as some different options of combination treatment. Combination bronchodilator therapy compared to monotherapy or LABA/GCS was found to be more effective in the context of exacerbations. Triple therapy (bronchodilators plus GCS) should be indicated in patients with dyspnoea and exacerbations – at least in the past two years.

keywords:

LABA/LAMA in the treatment of chronic obstructive pulmonary disease based on the latest research results

Małgorzata Farnik

chronic obstructive pulmonary disease (COPD), bronchodilator, long-acting muscarinic antagonists, long-acting beta-agonists, combination therapy